Double antibody attack: early trial combines immune and Growth-Signal blockers against advanced cancers
NCT ID NCT04739111
First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time
Summary
This early-stage trial is testing a combination of two lab-made antibodies in people with advanced solid tumors that have not responded to standard treatments. One antibody (LDP) aims to reactivate the immune system against cancer, while the other (CDP1) blocks a growth signal on cancer cells. The main goals are to evaluate safety, identify side effects, and determine the best dose for future studies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- LDP (anti-PD-L1 antibody) combined with CDP1 (anti-EGFR antibody)
- What this could lead to
- If safe and effective, this combination could offer a new treatment option for people with advanced cancers that have not responded to other therapies.
- What could go wrong
- This is a very early (Phase 1) trial with only 12 participants, so it is primarily testing safety and dosing. The combination may not shrink tumors or may cause significant side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dragonboat Biopharmaceutical,Co.,Ltd
Shanghai, Shanghai Municipality, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Chest-Injected drug drain Cancer's fluid trap?
- A safer first cut? trial tests two laparoscopic entry points for endometrial cancer surgery
- Can we predict who will survive a bowel surgery leak?
- Can a new nucleotide analogue boost cancer treatment?
- Can a pill that blocks multiple cancer proteins shrink Hard-to-Treat tumors?
- Can a single Protein's mutations predict esophageal cancer outcomes?